Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
PHASE 3 STUDY OF COMBINATION PEMBROLIZUMAB plus OLAPARIB THERAPY VERSUS ENZALUTAMIDE/ABIRATERONE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) AFTER PROGRESSION ON CHEMOTHERAPY (KEYLYNK-010)
- Authors
- Yu, E[Yu, Evan]; Park, SH[Park, Se Hoon]; Huang, YH[Huang, Yi-Hsiu]; Bennamoun, M[Bennamoun, Mostefa]; Xu, L[Xu, Lu]; Kim, J[Kim, Jeri]; Antonarakis, E[Antonarakis, Emmanuel]
- Issue Date
- Nov-2020
- Publisher
- BMJ PUBLISHING GROUP
- Citation
- JOURNAL FOR IMMUNOTHERAPY OF CANCER, v.8, pp.A210 - A211
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL FOR IMMUNOTHERAPY OF CANCER
- Volume
- 8
- Start Page
- A210
- End Page
- A211
- ISSN
- 2051-1426
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.